Lyell Immunopharma (LYEL) Accumulated Expenses (2020 - 2026)

Lyell Immunopharma has reported Accumulated Expenses for 7 years, with the latest figure at $31.5 million in Q1 2026.

• Quarterly Accumulated Expenses rose 1.0% year-over-year to $31.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.5 million (up 1.0% YoY) and the FY2025 annual result came in at $46.5 million, up 13.96% from the prior year.
• Accumulated Expenses declined to $31.5 million in Q1 2026 per LYEL's latest filing, from $46.5 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $46.5 million in Q4 2025 and troughed at $21.4 million in Q2 2022.
• A 5-year average of $28.7 million and a median of $28.1 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses retreated 16.32% in 2022, then surged 45.14% in 2024.
• Over 5 years, Accumulated Expenses stood at $28.8 million in 2022, then declined by 2.19% to $28.1 million in 2023, then surged by 45.14% to $40.8 million in 2024, then rose by 13.96% to $46.5 million in 2025, then tumbled by 32.33% to $31.5 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $31.5 million, $46.5 million, and $29.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.